Jennison Associates LLC Raises Stock Position in Savara Inc (NASDAQ:SVRA)

Jennison Associates LLC boosted its position in shares of Savara Inc (NASDAQ:SVRA) by 17.5% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 6,732,776 shares of the company’s stock after acquiring an additional 1,001,296 shares during the period. Jennison Associates LLC owned 4.09% of Savara worth $28,547,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors also recently bought and sold shares of the company. Janus Henderson Group PLC lifted its holdings in shares of Savara by 41.1% during the 1st quarter. Janus Henderson Group PLC now owns 2,563,620 shares of the company’s stock valued at $12,754,000 after purchasing an additional 746,407 shares during the last quarter. Vanguard Group Inc. raised its stake in Savara by 2.5% in the first quarter. Vanguard Group Inc. now owns 6,063,620 shares of the company’s stock valued at $30,197,000 after buying an additional 148,673 shares during the last quarter. Swiss National Bank acquired a new stake in Savara in the first quarter worth about $732,000. Frazier Life Sciences Management L.P. grew its stake in shares of Savara by 103.9% during the second quarter. Frazier Life Sciences Management L.P. now owns 8,157,385 shares of the company’s stock worth $32,874,000 after acquiring an additional 4,157,385 shares during the last quarter. Finally, Nantahala Capital Management LLC increased its holdings in shares of Savara by 198.2% during the second quarter. Nantahala Capital Management LLC now owns 5,180,951 shares of the company’s stock valued at $20,879,000 after acquiring an additional 3,443,541 shares in the last quarter. 87.93% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other Savara news, Director Joseph S. Mccracken purchased 20,000 shares of the stock in a transaction on Tuesday, November 19th. The shares were bought at an average price of $2.95 per share, for a total transaction of $59,000.00. Following the completion of the transaction, the director now owns 210,837 shares of the company’s stock, valued at $621,969.15. This trade represents a 10.48 % increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link. 5.13% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

A number of analysts recently commented on the stock. HC Wainwright lowered their target price on shares of Savara from $10.00 to $6.00 and set a “buy” rating for the company in a research note on Wednesday, November 13th. JMP Securities reissued a “market outperform” rating and set a $9.00 price objective on shares of Savara in a report on Tuesday, October 1st. Finally, Evercore ISI restated an “in-line” rating and issued a $5.00 target price (down previously from $7.00) on shares of Savara in a research note on Wednesday, November 13th. One research analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $10.17.

Savara Price Performance

Shares of SVRA opened at $3.25 on Friday. The business’s 50-day moving average is $3.78 and its two-hundred day moving average is $4.14. The company has a market capitalization of $556.91 million, a P/E ratio of -7.55 and a beta of 1.02. Savara Inc has a fifty-two week low of $2.82 and a fifty-two week high of $5.70. The company has a debt-to-equity ratio of 0.13, a quick ratio of 17.70 and a current ratio of 17.70.

Savara (NASDAQ:SVRA) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($0.11) earnings per share for the quarter, meeting the consensus estimate of ($0.11). Research analysts predict that Savara Inc will post -0.45 earnings per share for the current year.

Savara Company Profile

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.